<i>KRAS</i> p.G12C mutated-targeted treatments in metastatic colorectal cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. The presence of the KRAS G12C mutation in patients with CRC is associated with poor responses to standard therapies and worse outcomes. This study systematically reviewed and analyzed the existing evidence on the efficacy of KRAS G12C inhibitors.

Methods

PubMed, Scopus, and ISI Web of Knowledge were searched, along with conference proceedings, posters, and major oncology journals. Eligibility criteria included clinical trials involving adult patients with KRAS G12C-mutant CRC. Data on treatment outcomes, study design, and patient demographics were extracted and analyzed using a random-effects model, with heterogeneity assessed via I2 statistics.

Results

SUBMITTER: Vlachou MS 

PROVIDER: S-EPMC12850691 | biostudies-literature | 2026 Jan-Feb

REPOSITORIES: biostudies-literature